LeMaitre Vascular (NSDQ:LMAT) said last week that it agreed to put up $14 million for tissue preservation service provider Restore Flow Allografts. The deal calls for Burlington, Mass.-based LeMaitre to pay $12 million up front and another $2 million in May 2018, plus earn-puts pegged to sales performance over the next 2 years. Fox River Grove, Ill.-based Restore […]
LeMaitre Vascular Inc.
LeMaitre wins Chinese clearance for Trivex phlebectomy system
LeMaitre Vascular (NSDQ:LMAT) said last Friday it won clearance from China’s Food and Drug Administration for its Trivex transilluminated powered phlebectomy system. The Trivex system is designed to offer a minimally invasive option for removing varicose veins, the Burlington, Mass.-based company said. “We are pleased to receive this approval in the timeframe we expected. It […]
Ex-Medtronic strategy veep Oesterle joins VC shop New Enterprise Associates | Personnel Moves
Venture capital firm New Enterprise Associates said today it picked up ex-Medtronic (NYSE:MDT) executive veep Dr. Stephen Oesterle as a venture partner for the firm. Prior to being an executive veep for the medical giant, Oesterle served as senior veep of medicine and technology, and served as a member of the executive committee for 14 years, […]
Ex-FDA chief Hamburg moves to Institute of Medicine | Personnel Moves
Dr. Margaret Hamburg, who resigned as FDA commissioner in February, was named foreign secretary of the U.S. Institute of Medicine this week.
Hamburg spent 6 years leading the federal safety watchdog, overseeing a massive revamp of its medical device, drug, food and tobacco regulation.
LeMaitre pays $7.7M for Xenotis and its bio-graft
LeMaitre Vascular (NSDQ:LMAT) got a Wall Street boost today after reporting that it acquired graft-maker Xenotis is a deal valued at $7.7 million.
LeMaitre Vascular scoops up InaVein for $2.5M
LeMaitre Vascular (NSDQ:LMAT) is jumping into the varicose vein removal business with a $2.5 million buyout of InaVein. The Burlington, Mass.-based vascular device maker snatched up InaVein for more than 100% more than the company’s 2012 sales, according to a company statement.
LeMaitre doesn’t win much Wall Street favor with record sales in Q2
LeMaitre Vascular (NSDQ:LMAT) posted an 8% bump in profits for its 2nd quarter and raised guidance estimates for the year, but Wall Street was less than enthused.
LeMaitre graft recall gets FDA’s highest warning
The FDA put its highest-risk Class I label on a recall issued by LeMaitre Vascular (NSDQ:LMAT) over leakage concerns for the Albograft vascular grafts.
Hot topics: M&A, IP, Financing, and Products Liability Trends for medical device companies
Overview: IP/Technology Track: Hot topics: M&A, IP, Financing, and Products Liability Trends for medical device companies, featuring representatives from Allied Minds, Stryker, and LeMaitre Vascular. Hosted and moderated by Greenberg Traurig.
Moderator: David Dykeman, Shareholder & Patent Attorney, Greenberg Traurig (Moderator)
Confirmed Panelists:
LeMaitre Vascular ticks up on 120% Q1 profit jump
Profits soared 120% for LeMaitre Vascular (NSDQ:LMAT) during the 1st quarter on its 2nd consecutive quarter of double-digit sales growth, as the medical device company beat Wall Street’s earnings expectations by a penny.